Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 9/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.32 |
| ▸ | CD44 | P16070 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31469933 | 0.79 | CXCR2 (0.44) | CXCR2CA12CA1CA2CA9 | |
| SCHEMBL31470113 | 0.79 | CA12 (0.50) | CXCR2CA12CA1CA2CA9 | |
| SCHEMBL22616605 | 0.73 | CA12 (0.62) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL31470102 | 0.70 | CXCR2 (0.51) | CXCR2CA12CA1CA2CA9 | |
| SCHEMBL31470092 | 0.70 | CXCR2 (0.51) | CXCR2CA12CA1CA2CA9 | |
| SCHEMBL31469966 | 0.69 | CXCR2 (0.50) | CXCR2CA12CA1CA2CA9 | |
| SCHEMBL31470041 | 0.69 | CXCR2 (0.40) | CXCR2CA12CA1CA2CA9 | |
| SCHEMBL31470022 | 0.68 | CXCR2 (0.39) | CXCR2CA12CA1CA2CA9 | |
| SCHEMBL31470087 | 0.68 | CXCR2 (0.39) | CXCR2CA12CA1CA2CA9 | |
| SCHEMBL11165904 | 0.68 | CXCR2 (0.37) | CXCR2CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170141-A1 | MRGPRX2 MODULATORS AND RELATED METHODS OF TREATMENT | INCYTE CORPORATION | 2025-05-29 | — | — | US | disclosed |
| WO-2025076455-A1 | MRGPRX2 MODULATORS AND RELATED METHODS OF TREATMENT | Escient Pharmaceuticals Inc. (US) | 2025-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170141-A1 | MRGPRX2 MODULATORS AND RELATED METHODS OF TREATMENT | MRGPRX2, MRGPRX1, MRGPRX4 | CXCR2 763/4885CA12 3128/4885CA1 2789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.